3805 Old Easton Road
Doylestown, PA 18902
United States
617 463 9385
https://www.aprea.com
Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 7
Nom | Titre | Payer | Exercé | Année de naissance |
---|---|---|---|---|
Dr. Oren Gilad Ph.D. | Co-Founder, CEO, President & Director | 796,95k | S.O. | 1968 |
Mr. John P. Hamill CPA | Senior VP, CFO, Principal Accounting Officer & Secretary | 610,23k | S.O. | 1964 |
Dr. Dansu Li Ph.D. | Head of Technology | S.O. | S.O. | S.O. |
Dr. Lars B. Abrahmsen Ph.D. | Senior VP & Chief Scientific Officer | S.O. | S.O. | 1957 |
Mr. Brian Wiley | Senior Vice President of Corporate Development & Strategy | S.O. | S.O. | 1968 |
Dr. Michel Afargan Ph.D. | Head of Pharmacology Development | S.O. | S.O. | S.O. |
Mr. Ze'ev Weiss B.Sc., C.P.A. | Chief Business Advisor | S.O. | S.O. | 1962 |
Dr. Nadeem Q. Mirza M.D., M.P.H. | Chief Medical Officer | S.O. | S.O. | S.O. |
Ms. Andrea Epstein | Controller | S.O. | S.O. | S.O. |
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.
L’ISS Governance QualityScore de Aprea Therapeutics, Inc. en date du 1 mai 2024 est 8. Les scores principaux sont Audit : 3; Société : 7; Droits des actionnaires : 8; Compensation : 9.